We retrospectively assessed breakthrough invasive fungal infections (b-IFIs) in 100 consecutive patients with leukemia receiving single-agent isavuconazole; 13 had documented b-IFIs (candidiasis in 6, mucormycosis in 4). All b-IFIs were observed in patients with prolonged neutropenia and active leukemia.
CITATION STYLE
Rausch, C. R., Dipippo, A. J., Bose, P., & Kontoyiannis, D. P. (2018). Breakthrough fungal infections in patients with leukemia receiving isavuconazole. Clinical Infectious Diseases, 67(10), 1610–1613. https://doi.org/10.1093/cid/ciy406
Mendeley helps you to discover research relevant for your work.